Goldman Sachs’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-377,718
| Closed | -$83.4M | – | 6532 |
|
|
2025
Q4 | $83.4M | Buy |
377,718
+107,714
| +40% | +$17.4M | 0.01% | 1121 |
|
|
2025
Q3 | $25.9M | Buy |
270,004
+265,289
| +5,626% | +$16.9M | ﹤0.01% | 2001 |
|
|
2025
Q2 | $230K | Sell |
4,715
-37,428
| -89% | -$899K | ﹤0.01% | 5589 |
|
|
2025
Q1 | $908K | Buy |
42,143
+28,273
| +204% | +$628K | ﹤0.01% | 4753 |
|
|
2024
Q4 | $373K | Buy |
+13,870
| New | +$225K | ﹤0.01% | 5402 |
|
|
2023
Q1 | – | Sell |
-3,355
| Closed | -$50.7K | – | 5943 |
|
|
2022
Q4 | $50.7K | Sell |
3,355
-265
| -7% | -$3.16K | ﹤0.01% | 5596 |
|
|
2022
Q3 | $45K | Sell |
3,620
-308
| -8% | -$4.25K | ﹤0.01% | 5812 |
|
|
2022
Q2 | $38K | Buy |
3,928
+164
| +4% | +$2.03K | ﹤0.01% | 6081 |
|
|
2022
Q1 | $63K | Sell |
3,764
-20
| -0.5% | -$339 | ﹤0.01% | 6218 |
|
|
2021
Q4 | $96K | Sell |
3,784
-1,711
| -31% | -$53.3K | ﹤0.01% | 6144 |
|
|
2021
Q3 | $246K | Sell |
5,495
-1,139
| -17% | -$43.3K | ﹤0.01% | 5614 |
|
|
2021
Q2 | $268K | Sell |
6,634
-1,339
| -17% | -$56.7K | ﹤0.01% | 5581 |
|
|
2021
Q1 | $425K | Buy |
7,973
+5,523
| +225% | +$273K | ﹤0.01% | 5234 |
|
|
2020
Q4 | $98K | Sell |
2,450
-7,241
| -75% | -$360K | ﹤0.01% | 5295 |
|
|
2020
Q3 | $553K | Buy |
9,691
+7,317
| +308% | +$517K | ﹤0.01% | 4431 |
|
|
2020
Q2 | $175K | Sell |
2,374
-639
| -21% | -$41.4K | ﹤0.01% | 4839 |
|
|
2020
Q1 | $149K | Buy |
3,013
+50
| +2% | +$3K | ﹤0.01% | 4811 |
|
|
2019
Q4 | $228K | Sell |
2,963
-914
| -24% | -$41.8K | ﹤0.01% | 4847 |
|
|
2019
Q3 | $155K | Buy |
3,877
+352
| +10% | +$11.8K | ﹤0.01% | 4888 |
|
|
2019
Q2 | $118K | Buy |
3,525
+30
| +0.9% | +$1.25K | ﹤0.01% | 4896 |
|
|
2019
Q1 | $185K | Sell |
3,495
-936
| -21% | -$51.3K | ﹤0.01% | 4817 |
|
|
2018
Q4 | $208K | Sell |
4,431
-833
| -16% | -$59.5K | ﹤0.01% | 4810 |
|
|
2018
Q3 | $463K | Buy |
5,264
+222
| +4% | +$19.6K | ﹤0.01% | 4460 |
|
|
2018
Q2 | $524K | Sell |
5,042
-67
| -1% | -$6.33K | ﹤0.01% | 4479 |
|
|
2018
Q1 | $409K | Buy |
+5,109
| New | +$698K | ﹤0.01% | 4602 |
|
|
2017
Q3 | – | Sell |
-4,332
| Closed | -$650K | – | 6672 |
|
|
2017
Q2 | $650K | Buy |
+4,332
| New | +$599K | ﹤0.01% | 4858 |
|
|
2016
Q3 | – | Sell |
-511
| Closed | -$105K | – | 7026 |
|
|
2016
Q2 | $105K | Sell |
511
-13,220
| -96% | -$3.2M | ﹤0.01% | 6104 |
|
|
2016
Q1 | $3.49M | Sell |
13,731
-13,559
| -50% | -$3.12M | ﹤0.01% | 2998 |
|
|
2015
Q4 | $9.37M | Buy |
27,290
+10,716
| +65% | +$3.22M | ﹤0.01% | 2300 |
|
|
2015
Q3 | $4.22M | Buy |
16,574
+218
| +1% | +$62.3K | ﹤0.01% | 3035 |
|
|
2015
Q2 | $4.59M | Buy |
+16,356
| New | +$5.03M | ﹤0.01% | 3042 |
|
Goldman Sachs's CDTX Position: Q1 2026 in Review
Goldman Sachs sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 377,718 shares — an estimated $83.4M sold.
Goldman Sachs first reported a position in CDTX in Q2 2015 and held it in 31 quarters. The position peaked at $83.4M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Goldman Sachs reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 377,718 Cidara Therapeutics shares in Q1 2026, an estimated $83.4M.
- Goldman Sachs first reported a position in Cidara Therapeutics in Q2 2015 and held it in 31 quarters.
- Goldman Sachs's Cidara Therapeutics position peaked at $83.4M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.